Cargando…
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subse...
Autores principales: | Yu, Irene, Dakwar, Anthony, Takabe, Kazuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856401/ https://www.ncbi.nlm.nih.gov/pubmed/36672193 http://dx.doi.org/10.3390/cells12020258 |
Ejemplares similares
-
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020) -
Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
por: Kanani, A, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020) -
Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
por: Yamashita, Kimihiro, et al.
Publicado: (2018) -
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)